Therapeutic effects of docosahexaenoic acid ethyl ester in patients with generalized peroxisomal disorders

American Journal of Clinical Nutrition

Volumn 71, Issue 1 SUPPL., 2000, Pages

  Martínez, Manuela ^a   Vázquez, Elida ^b   García Silva, M Teresa ^b   Manzanares, Javier ^b   Bertran, José M ^b   Castelló, Francisco ^b   Mougan, Isabel ^b  

^a Laboratoris Clinics Hosp Vall d'H   (Spain)

^b NONE

Author keywords

Docosahexaenoic acid; Magnetic resonance imaging; Peroxisomal disorders; Plasmalogens; Very long chain fatty acids; Zellweger syndrome

Indexed keywords

DOCOSAHEXAENOIC ACID; PLASMALOGEN; VERY LONG CHAIN FATTY ACID;

ADOLESCENT; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; DISORDERS OF PEROXISOMAL FUNCTIONS; DRUG EFFECT; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRESCHOOL CHILD; SCHOOL CHILD; TREATMENT INDICATION; TREATMENT OUTCOME; ZELLWEGER SYNDROME;

EID: 0033964508     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/71.1.376s     Document Type: Conference Paper

References (37)

1. Rhodin J. Correlation of ultrastructural organization and function in normal and experimentally changed proximal convoluted tubule cells of the mouse kidney. PhD dissertation. Aktiebolaget Godvil, Stockholm, 1954.
2. De Duve C, Baudhuin P. Peroxisomes (microbodies and related particles). Physiol Rev 1966;46:323-57.
3. Goldfischer S, Moore CL, Johnson AB, et al. Peroxisomal and mitochondrial defects in the cerebro-hepato-renal syndrome. Science 1973:182:62-4.
4. Bowen P, Lee CSM, Zellweger H, et al. A familial syndrome of multiple congenital defects. Bull Johns Hopkins Hosp 1964;114:402-14.
5. Singh I, Moser AB, Goldfischer S, et al. Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy. Proc Natl Acad Sci U S A 1984:81:4203-7.
6. Wanders RJA, van Roermund CWT, van Wijland MJA, et al. Peroxisomal fatty acid β-oxidation in relation to the accumulation of very long chain fatty acids in cultured skin fibroblasts from patients with Zellweger syndrome and other peroxisomal disorders. J Clin Invest 1987;80:1778-83.
7. Lazarow PB, Moser HW. Disorders of peroxisome biogenesis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, ed. The metabolic basis of inherited disease. 6th ed. New York: McGraw-Hill, 1995: 2287-324.
8. Sing H, Pahan K, Singh K, et al. Refsum disease: a defect in the α-oxidation of phytanic acid in peroxisomes. J Lipid Res 1993;34: 1755-64.
9. Hajra AK, Bishop JE. Glycerolipid biosynthesis in peroxisomes via the acyl dihydroxyacetonephosphate pathway. Ann N Y Acad Sci 1982;386:170-82.
10. Moser AB, Singh I, Brown FR III, et al. The cerebro-hepato-renal (Zellweger) syndrome: increased levels and impaired degradation of very long chain fatty acids and their usein prenatal diagnosis. N Engl J Med 1984;310:1141-6.
11. Bakkeren JA, Monnens LAH, Trijbels JMF, et al. Serum very long chain fatty acid pattern in Zellweger syndrome. Clin Chim Acta 1984;138:325-30.
12. Heymans HSA, Schutgens RBH, Tan R, et al. Severe plasmalogen deficiency in tissues of infants without peroxisomes (Zellweger syndrome). Nature 1983;306:69-70.
13. Datta NS, Wilson GN, Hajra AK. Deficiency of enzymes catalyzing the biosynthesis of glycerol-ether lipids in Zellweger syndrome. N Engl J Med 1984;311:1080-3.
14. Bjorkhem I, Sisfontes L, Bostrom B, et al. Simple diagnosis of the Zellweger syndrome by gas-liquid chromatography of dimethylacetals. J Lipid Res 1986;27:786-91.
15. Poulos A, Sharp P, Fellenberg AJ, et al. Cerebro-hepato-renal (Zellweger) syndrome, adrenoleukodystrophy and Refsum's disease: plasma changes and skin fibroblast phytanic acid oxidase. Hum Genet 1985;70:172-7.
16. Poll-The BT, Saudubray JM, Ogier H, et al. Infantile Refsum's disease: biochemical findings suggesting multiple peroxisomal dysfunction. J Inherit Metab Dis 1986;9:169-74.
17. Hanson RF, Szczepanik-van Leeuwen P, Williams GC, et al. Defects of bile acids synthesis in Zellweger's syndrome. Science 1979; 203:1107-8.
18. Jaffe R, Crumrine P, Hashida Y, et al. Neonatal adrenoleukodystrophy: clinical, pathological, and biochemical delineation of a syndrome affecting both males and females. Am J Pathol 1982;108:100-11.
19. Scotto JM, Hadchouel M, Odièvre M, et al. Infantile phytanic acid storage disease, a possible variant of Refsum's disease: three cases including ultrastructural studies of the liver. J Inherit Metab Dis 1982;5:83-90.
20. Moser AB, Borel J, Odone A, et al. A new dietary therapy for adrenoleukodystrophy: biochemical and preliminary clinical results in 36 patients. Ann Neurol 1987;21:240-9.
21. Smeitink JMA, Beemer FA, Speel M, et al. Bone dysplasia associated with phytanic acid accumulation and deficient plasmalogen synthesis: a peroxisomal entity amenable to plasmapheresis. J Inherit Metab Dis 1992;15:377-80.
22. Wilson GN, Holmes RG, Custer J, et al. Zellweger syndrome: diagnostic assays, syndrome delineation, and potential therapy. Am J Med Genet 1986;24:69-82.
23. Setchell KDR, Bragetti P, Zimmer-Nechemias L, et al. Oral bile acid treatment and the patient with Zellweger syndrome. Hepatology 1992;15:198-207.
24. Martinez M. Polyunsaturated fatty acid changes suggesting a new enzymatic defect in Zellweger syndrome. Lipids 1989;24:261-5.
25. Martinez M. Severe deficiency of docosahexaenoic acid in peroxisomal disorders: a defect of D4 desaturation? Neurology 1990;40:1292-8.
26. Martinez M. Abnormal profiles of polyunsaturated fatty acids in the brain, liver, kidney and retina of patients with peroxisomal disorders. Brain Res 1992;583:171-82.
27. Anderson RE, Benolken RM, Dudley PA, et al. Exp Eye Res 1974;18:205-3.
28. Salem N Jr, Niebylski CD. The nervous system has an absolute molecular species requirement for proper function. Mol Membr Biol 1995;12:131-4.
29. Martinez M, Pineda M, Vidal R, et al. Docosahexaenoic acid - a new therapeutic approach to peroxisomal-disorder patients: experience with two cases. Neurology 1993;43:1389-97.
30. Martinez M. Polyunsaturated fatty acids in the developing human brain, erythrocytes and plasma in peroxisomal disease: therapeutic implications. J Inherit Metab Dis 1995;18(suppl):61-75.
31. Martinez M. Docosahexaenoic acid therapy in DHA-deficient patients with disorders of peroxisomal biogenesis. Lipids 1996;31:S145-52.
32. Martinez M, Vázquez L. Treatment with docosahexaenoic acid ethyl ester improves myelination in patients with generalized peroxisomal disorders. Neurology 1998;51:26-32.
33. Moser A, Rasmussen M, Naidu S, et al. Phenotype of patients with peroxisomal disorders subdivided into sixteen complementation groups. J Pediatr 1995;125:755-67.
34. Lepage G, Roy CC. Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res 1986;27:114-20.
35. Martinez M, Mougan I, Roig M, et al. Blood polyunsaturated fatty acids in patients with peroxisomal disorders. A multicenter study. Lipids 1994;29:273-80.
36. Christie WW, Brechany EY, Johnson SB, et al. A comparison of pyrrolidide and picolinyl ester derivatives for the identification of fatty acids in natural samples by gas chromatography-mass spectrometry. Lipids 1986;21:657-61.
37. Voss A, Reinhart M, Sankarappa S, et al. The metabolism of 7,10,13,16,19-docosapentaenoic acid to 4,7,10,13,16,19-docosahexaenoic acid in rat liver is independent of a 4-desaturase. J Biol Chem 1991;266:19995-20000.